// App-Quantinova.ai

2747 : PARP inhibitors act synergistically with cisplatin and doxorubicin in BRCA competent cells by compromising chemotherapy-induced replication arrest

Researchers

Presenter

  • Lea Schaaf

Principal Investigators

  • Matthias Schwab

  • Simon Heine

  • Walter E. Aulitzky

  • Heiko van der Kuip

Medical Centers

  • Dr. Margarete Fischer-Bosch Institute and University of Tuebingen, Stuttgart, Germany

  • Dr. Margarete Fischer-Bosch Institute and Department of Clinical Pharmacology, University Hospital Tuebingen, Stuttgart and Tuebingen, Germany

  • Robert Bosch Hospital, Stuttgart, Germany.

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Poly(ADP-Ribose) Polymerase 1

  • Histone H2AX

  • Tumor suppressor p53-binding protein 1

  • BRCA mutation

Drug/Treatment

  • Doxorubicin

  • Paclitaxel

  • Rucaparib

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved